Get started
GINKGO BIOWORKS HOLDINGS INCGINKGO BIOWORKS HOLDINGS INCGINKGO BIOWORKS HOLDINGS INC

GINKGO BIOWORKS HOLDINGS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

DNA chart


Full chart

DNA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪12.64 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−254.17 MXN
Net income (FY)
‪−15.17 B‬ MXN
Revenue (FY)
‪4.27 B‬ MXN
Shares float
‪36.50 M‬
Beta (1Y)
2.61

Employees


Employees (FY)
‪1.22 K‬
Change (1Y)
−74 −5.73%
Revenue / Employee (1Y)
‪3.51 M‬ MXN
Net income / Employee (1Y)
‪−12.45 M‬ MXN

About Ginkgo Bioworks Holdings, Inc.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Jason Kelly
Website
ginkgobioworks.com
Headquarters
Boston
Founded
2008
FIGI
BBG01B347V60
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

DNA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of DNA is 262.00 MXN — it has increased by 0.38% in the past 24 hours. Watch GINKGO BIOWORKS HOLDINGS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange GINKGO BIOWORKS HOLDINGS INC stocks are traded under the ticker DNA.
DNA stock has risen by 0.38% compared to the previous week, the month change is a 59.76% rise, over the last year GINKGO BIOWORKS HOLDINGS INC has showed a −68.81% decrease.
We've gathered analysts' opinions on GINKGO BIOWORKS HOLDINGS INC future price: according to them, DNA price has a max estimate of 330.95 MXN and a min estimate of 124.11 MXN. Watch DNA chart and read a more detailed GINKGO BIOWORKS HOLDINGS INC stock forecast: see what analysts think of GINKGO BIOWORKS HOLDINGS INC and suggest that you do with its stocks.
DNA reached its all-time high on Nov 3, 2022 with the price of 2,160.00 MXN, and its all-time low was 164.00 MXN and was reached on Nov 26, 2024. View more price dynamics on DNA chart.
See other stocks reaching their highest and lowest prices.
DNA stock is 0.38% volatile and has beta coefficient of 2.61. Track GINKGO BIOWORKS HOLDINGS INC stock price on the chart and check out the list of the most volatile stocks — is GINKGO BIOWORKS HOLDINGS INC there?
Today GINKGO BIOWORKS HOLDINGS INC has the market capitalization of ‪11.98 B‬, it has decreased by −24.42% over the last week.
Yes, you can track GINKGO BIOWORKS HOLDINGS INC financials in yearly and quarterly reports right on TradingView.
GINKGO BIOWORKS HOLDINGS INC is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
DNA earnings for the last quarter are −21.28 MXN per share, whereas the estimation was −53.76 MXN resulting in a 60.41% surprise. The estimated earnings for the next quarter are −31.36 MXN per share. See more details about GINKGO BIOWORKS HOLDINGS INC earnings.
GINKGO BIOWORKS HOLDINGS INC revenue for the last quarter amounts to ‪1.75 B‬ MXN, despite the estimated figure of ‪886.48 M‬ MXN. In the next quarter, revenue is expected to reach ‪927.07 M‬ MXN.
DNA net income for the last quarter is ‪−1.11 B‬ MXN, while the quarter before that showed ‪−3.98 B‬ MXN of net income which accounts for 72.10% change. Track more GINKGO BIOWORKS HOLDINGS INC financial stats to get the full picture.
No, DNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 24, 2025, the company has ‪1.22 K‬ employees. See our rating of the largest employees — is GINKGO BIOWORKS HOLDINGS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GINKGO BIOWORKS HOLDINGS INC EBITDA is ‪−8.97 B‬ MXN, and current EBITDA margin is −238.88%. See more stats in GINKGO BIOWORKS HOLDINGS INC financial statements.
Like other stocks, DNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GINKGO BIOWORKS HOLDINGS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GINKGO BIOWORKS HOLDINGS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GINKGO BIOWORKS HOLDINGS INC stock shows the buy signal. See more of GINKGO BIOWORKS HOLDINGS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.